ABIVAX — Capital/Financing Update 2016

Jan 8, 2016

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT AT 31 DECEMBER 2015

Paris, January 8th, 2016

Regarding the liquidity contract assigned by ABIVAX (ISIN code: FR0012333284, ticker: ABVX) to TSAF – Tradition Securities And Futures – on June 26th, 2015, the liquidity account held the following amounts on December 31, 2015:

• 43,446 shares
• €195,505.60

As a reminder, the liquidity account held the following amounts at June 30, 2015:

• 600 shares
• €987,010.50

ABIVAX is an emerging global leader in the discovery, development and commercialization of antiviral therapeutics and vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

Contacts : Investor Relations Raquel Lizarraga raquel.lizarraga@abivax.com +33 1 53 83 09 63

Citigate Dewe Rogerson Lucie Larguier abivax@citigate.fr +33 1 53 32 84 75

Press Relations ALIZE RP Caroline Carmagnol and Florence Portejoie abivax@alizerp.com +33 6 64 18 99 59 / + 33 1 44 54 36 64